ALEX Trial: Alectinib vs Crizotinib in ALK-Positive NSCLC

Description: H. Jack West, MD of Swedish Cancer Institute discusses the results of the ALEX trial for ALK+ non-small cell lung cancer. This was recorded at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract LBA9008: Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study
Shared By : AnnualMeeting2017
Posted on : 06/16/17
Added : 5 months ago


Nothing found.

More From AnnualMeeting2017

Nothing found.